Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid AntibodiesRuiz-Irastorza, G., Cuadrado, M. J., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V., Pierangeli, S., Tektonidou, M. & Khamashta, M., Feb-2011, In : Lupus. 20, 2, p. 206-218 13 p.
Research output: Contribution to journal › Article › Academic › peer-review
The antiphospholipid syndrome (APS) is defined by the presence of thrombosis and/or pregnancy morbidity in combination with the persistent presence of circulating antiphospholipid antibodies: lupus anticoagulant, anticardiolipin antibodies and/or anti-beta 2-glycoprotein I antibodies in medium to high titers. The management of thrombosis in patients with APS is a subject of controversy. This set of recommendations is the result of an effort to produce guidelines for therapy within a group of specialist physicians in Cardiology, Neurology, Hematology, Rheumatology and Internal Medicine, with a clinical and research focus on APS. Lupus (2011) 20, 206-218.
|Number of pages||13|
|Publication status||Published - Feb-2011|
- anticardiolipin, antiphospholipid, aspirin, hydroxychloroquine, lupus anticoagulant, prevention, stroke, thrombosis, warfarin, SYSTEMIC-LUPUS-ERYTHEMATOSUS, RISK-FACTORS, ANTICARDIOLIPIN ANTIBODIES, ISCHEMIC-STROKE, VENOUS THROMBOEMBOLISM, ANTITHROMBOTIC THERAPY, ANTICOAGULANT-THERAPY, PHOSPHOLIPID SYNDROME, RECURRENT THROMBOSIS, CLINICAL-OUTCOMES